191% increase in CR%Not easy for new investors to make sense of what is coming in the Phase11 study data.
To make it very simple, let's just compare a group of verifiable undertreated patients, and a group of verifiable optimized patients from TLT Newsletters.
1) Undertreated patients(12).
From the 3Q2020 Newsletter.
CR..............3 patients......25%.
PR..............2 patients......16%
TR............. 5 patients.......41%
NR..............7 patients.......58%.
Total..........12 patients.
2) Optimized patients(11).
From the 3Q2021 Newsletter.
11 optimized patients(18-7 pending=11 patients).
CR..............8 patients........73%
PR..............2 patients........18%
TR.............10 patients........91%
NR..............1 patients..........9%
Total 11 patients.
The big difference is an increase of 191% in CR%(complete response).
As more optimized patients are treated the Phase11 study data will get better & better.